Antidepressant discontinuation syndrome: Estimated drug-specific incidence

Category	Antidepressant
Lowest rate (15% of patients)	Fluoxetine
Low to moderate rates (<30% of patients)	Agomelatine^*
	Bupropion
	Citalopram
	Duloxetine
	Levomilnacipran and milnacipran
	Mirtazapine
	Nefazodone
	Sertraline
	Vilazodone
	Vortioxetine
Higher rates (≥30% of patients)	Desvenlafaxine and venlafaxine
	Escitalopram
	Fluvoxamine
	Imipramine
	Paroxetine
Highest rates of severe discontinuation symptoms (5 to 10% of patients)	Imipramine
	Desvenlafaxine and venlafaxine
	Paroxetine

* Agomelatine is not available in the United States.

References:

Henssler J, Schmidt Y, Schmidt U, et al. Incidence of antidepressant discontinuation symptoms: A systematic review and meta-analysis. Lancet Psychiatry 2024; 11:526.
Lam RW, Kennedy SH, Adams C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023: Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes. Can J Psychiatry 2024; 69:641.

Graphic 148187 Version 1.0